NASDAQ:ADXS - Advaxis Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.63 -0.07 (-4.12 %)
(As of 06/24/2018 03:25 AM ET)
Previous Close$1.63
Today's Range$1.62 - $1.73
52-Week Range$1.51 - $7.45
Volume4.78 million shs
Average Volume609,956 shs
Market Capitalization$89.46 million
P/E Ratio-0.71
Dividend YieldN/A
Advaxis logoAdvaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based immunotherapies in the United States. It is developing Axalimogene filolisbac and ADXS-Dual that are Lm-LLO immunotherapy product candidates for the treatment of human papilloma virus associated cancers, including cervical, and head and neck cancers. The company is also developing Axalimogene filolisbac for the treatment of anal cancer; ADXS-PSA, an Lm-LLO immunotherapy product candidate, which is designed to target the prostate specific antigen associated with prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product candidate that is designed to create individualized therapies by activating the patient's immune system to respond against multiple mutations or neoantigens. In addition, it is developing ADXS-HOT for generating potent anti-cancer immunity; and ADXS-HER2, an Lm technology antigen delivery product candidate that is designed to target HER2 expressing solid tumors, including human and canine osteosarcoma. The company has collaboration and licensing agreements with Bristol-Myers Squibb Company; Amgen Inc.; Sellas Life Science Group; Merck & Co., Inc.; MedImmune/AstraZeneca PLC; Especificos Stendhal SA de CV; Aratana Therapeutics Inc.; and Global BioPharma Inc. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.

Receive ADXS News and Ratings via Email

Sign-up to receive the latest news and ratings for ADXS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations


Debt-to-Equity RatioN/A
Current Ratio3.47
Quick Ratio3.47


Trailing P/E Ratio-0.71
Forward P/E Ratio-1.20
P/E GrowthN/A

Sales & Book Value

Annual Sales$12.03 million
Price / Sales7.13
Cash FlowN/A
Price / CashN/A
Book Value$0.86 per share
Price / Book1.90


EPS (Most Recent Fiscal Year)($2.31)
Net Income$-93,430,000.00
Net Margins-1,041.73%
Return on Equity-168.35%
Return on Assets-99.50%


Outstanding Shares52,620,000

The Truth About Cryptocurrencies

Advaxis (NASDAQ:ADXS) Frequently Asked Questions

What is Advaxis' stock symbol?

Advaxis trades on the NASDAQ under the ticker symbol "ADXS."

How were Advaxis' earnings last quarter?

Advaxis, Inc. (NASDAQ:ADXS) posted its earnings results on Monday, March, 12th. The biotechnology company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.06. The biotechnology company earned $2.06 million during the quarter, compared to the consensus estimate of $3.03 million. Advaxis had a negative net margin of 1,041.73% and a negative return on equity of 168.35%. View Advaxis' Earnings History.

When is Advaxis' next earnings date?

Advaxis is scheduled to release their next quarterly earnings announcement on Monday, September, 10th 2018. View Earnings Estimates for Advaxis.

What price target have analysts set for ADXS?

3 brokers have issued twelve-month price targets for Advaxis' shares. Their forecasts range from $2.00 to $5.00. On average, they expect Advaxis' stock price to reach $3.3333 in the next twelve months. View Analyst Ratings for Advaxis.

What are Wall Street analysts saying about Advaxis stock?

Here are some recent quotes from research analysts about Advaxis stock:
  • 1. HC Wainwright analysts commented, "We base our $20 price target on probability-adjusted revenue forecasts for avacopan in AAV and C3G. We use the net present value of our revenue forecast through 2028, apply a 30% probability of success (POS) for avacopan in AAV, a 25% POS for avacopan in C3G, a 3x price/sales multiple, and our estimated fully diluted year- end 2018 net cash of $2.17/share to arrive at our price target. Our P/S multiple of 3x is in-line with ChemoCentryx’s peers that range between 2-5x. We use a 25% discount rate for the pipeline, which includes CCX140, CCX872 and avacopan for HS, as it is above the marketed products discount rate due to development risks but within the typical range of 15-25% for products in development. We project revenues of $72M for avacopan in AAV in 2021, growing to $1.4B in 2028. For avacopan in C3G, we estimate revenues of $10M in 2024, increasing to $124M in 2028." (6/8/2018)
  • 2. Cantor Fitzgerald analysts commented, "Multiple inflection points expected in 2018, including an update on the AIM2CERV Phase III study and potential preliminary data from Part B of the Phase I/II study of ADXS-PSA in combination with Keytruda." (9/25/2017)

Who are some of Advaxis' key competitors?

Who are Advaxis' key executives?

Advaxis' management team includes the folowing people:
  • Ms. Sara M. Bonstein, Exec. VP, Principal Accounting Officer, CFO & Corp. Sec. (Age 37)
  • Dr. Robert G. Petit, Exec. VP & Chief Scientific Officer (Age 58)
  • Mr. Anthony A. Lombardo, Interim Chief Exec. Officer (Age 69)
  • Mr. Christopher Duke, Sr. VP & COO
  • Mr. Mayo Pujols, Sr. VP of Technical Operations

Has Advaxis been receiving favorable news coverage?

News stories about ADXS stock have been trending somewhat positive recently, according to Accern Sentiment. Accern rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Advaxis earned a media sentiment score of 0.17 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 45.58 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Who are Advaxis' major shareholders?

Advaxis' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.59%) and DAFNA Capital Management LLC (1.33%). Company insiders that own Advaxis stock include Adage Capital Partners Gp, LL, Anthony A Lombardo, Daniel O'connor, David Sidransky, Gregory T Mayes, Richard J Berman, Robert Petit, Sara Bonstein and Thomas J Mckearn. View Institutional Ownership Trends for Advaxis.

Which institutional investors are buying Advaxis stock?

ADXS stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc. and DAFNA Capital Management LLC. View Insider Buying and Selling for Advaxis.

How do I buy shares of Advaxis?

Shares of ADXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Advaxis' stock price today?

One share of ADXS stock can currently be purchased for approximately $1.63.

How big of a company is Advaxis?

Advaxis has a market capitalization of $89.46 million and generates $12.03 million in revenue each year. The biotechnology company earns $-93,430,000.00 in net income (profit) each year or ($2.31) on an earnings per share basis. Advaxis employs 108 workers across the globe.

How can I contact Advaxis?

Advaxis' mailing address is 305 COLLEGE ROAD EAST, PRINCETON NJ, 08540. The biotechnology company can be reached via phone at 609-452-9813 or via email at [email protected]

MarketBeat Community Rating for Advaxis (ADXS)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  235 (Vote Outperform)
Underperform Votes:  136 (Vote Underperform)
Total Votes:  371
MarketBeat's community ratings are surveys of what our community members think about Advaxis and other stocks. Vote "Outperform" if you believe ADXS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADXS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/24/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.